CATX Profile
Perspective Therapeutics, Inc., a global leader in isotope-based medical technologies, specializes in the development, manufacturing, and marketing of innovative products for the treatment of cancer and other malignant diseases. The company's portfolio includes the CS-1 Cesium-131 brachytherapy seeds, which are utilized for targeted radiation therapy in various cancers such as prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.
These brachytherapy seeds deliver precise, localized radiation, minimizing damage to surrounding healthy tissues and improving treatment outcomes. Perspective Therapeutics' products are employed in a range of clinical settings, including surgical facilities and specialized medical practices, providing critical tools for oncologists and healthcare providers in managing complex cancer cases.
The company’s comprehensive approach includes not only the production of high-quality medical isotopes but also support for the integration and use of these products in clinical practice. Perspective Therapeutics works closely with healthcare providers to ensure the effective application of its technologies in patient care.
Founded in 1998 and headquartered in Richland, Washington, Perspective Therapeutics was previously known as Isoray, Inc. The company rebranded in February 2022 to better reflect its evolving focus and commitment to advancing therapeutic solutions. With a robust foundation in isotope-based therapies, Perspective Therapeutics continues to drive innovation in cancer treatment, aiming to enhance patient outcomes and expand its impact globally.
|
